Efficacy and safety of rituximab for intractable immunogenic neurological disorder in children

Efficacy and safety of rituximab for intractable immunogenic neurological disorder in children - rituximab for pediatric neurological disorder

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009421

Enrollment

Registered

2012-11-28

Start date

2012-06-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuromyelitis optica (NMO), opsoclonus-myoclonus syndrome (OMS)

Interventions

administration of rituximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The NMO and OMS patiets 1) are less than 18-year-old patient, 2) are not effective steroid, the plasma exchange, and immunoglobulin medication, or who are anxious about strong side effects, 3) are able to be hospitalized, 4) are obtained informed-consent.

Exclusion criteria

Exclusion criteria: The patients 1) are affected for infectious disease, 2) are recieved live vaccine within 4weeks, 3) are suffered from heart, lung, liver and kidney disease, 4) have the allergy for rituximab, 5) are ruled unfit to this study.

Design outcomes

Primary

Measure	Time frame
Clinical symptom, recurrence ratio, total dose of steroid	—

Countries

Japan

Contacts

Public ContactHiroaki Nagase

Kobe University Graduate School of Medicine Department of Pediatrics

nagase@med.kobe-u.ac.jp078-382-6090

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026